-+ 0.00%
-+ 0.00%
-+ 0.00%

Travere Therapeutics names Bradley Campbell CEO, effective Dec. 1, 2026

PUBT·09/21/2026 20:05:31
Listen to the news
Travere Therapeutics names Bradley Campbell CEO, effective Dec. 1, 2026
  • Travere Therapeutics named Bradley L. Campbell as president, CEO, board member, effective Dec. 1, 2026.
  • Outgoing CEO Eric Dube will serve until that date, then remain executive advisor through Feb. 15, 2027.
  • Campbell previously led Amicus Therapeutics as president and CEO; held commercial, business development roles at Genzyme, Bristol-Myers Squibb.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921057187) on September 21, 2026, and is solely responsible for the information contained therein.